Navigation Links
Micromet Announces Definitive Agreement for $40 Million Private Equity Placement
Date:9/30/2008

e Securities Act of 1933, as amended, or any state securities laws and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission (SEC) or an applicable exemption from the registration requirements. Micromet, Inc. has agreed to file a registration statement with respect to the shares within 30 calendar days after the closing date. This news release is being issued pursuant to and in accordance with Rule 135c under the Securities Act of 1933, as amended.

About Micromet, Inc.

Micromet, Inc. is a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. Four of its antibodies are currently in clinical trials, while the remainder of the product pipeline is in preclinical development. The BiTE(R) antibody blinatumomab (MT103/MEDI-538) is in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia and in a phase 1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma. BiTE antibodies represent a new class of antibodies that activate a patient's own cytotoxic T cells, considered the most powerful "killer cells" of the human immune system, to eliminate cancer cells. Micromet is developing blinatumomab in collaboration with MedImmune, Inc., a subsidiary of AstraZeneca plc. MT110 is the second BiTE antibody in clinical trials, and is being developed by Micromet in a phase 1 clinical trial for the treatment of patients with lung or gastrointestinal cancer. The third clinical stage antibody is adecatumumab, also known as MT201, a human monoclonal antibody that targets epithelial cell adhesion molecule (EpCAM)-expressing solid tumors. Micromet is developing adecatumumab in collaboration with Merck Serono in a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer. The fourth clinical stage antibody is MT293
'/>"/>

SOURCE Micromet, Inc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Micromet, Inc. Fills Audit Committee Vacancy and Regains Compliance With NASDAQ Marketplace Rule
2. Micromet, Inc. Appoints Barclay Phillips as Senior Vice President and Chief Financial Officer
3. Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
4. Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results
5. Micromet to Present at the Susquehanna Financial Groups SIGnificant Investment Options Conference on March 4, 2008
6. Micromet to Present at Two Upcoming Investor Conferences
7. Micromet to Present at the 2007 RBC Capital Markets Healthcare Conference on December 12, 2007
8. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
9. Micromet to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference on November 7, 2007
10. Micromet is Presenting Four Posters on BiTE(R) Antibodies at the International AACR-NCI-EORTC Conference
11. Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... India , August 28, 2015 ... by Product (Media, Sera, Cryogenic Storage Systems, Thawing Equipment, ... (Therapeutic, Regenerative Medicine, Clinical Trials), End User - Global ... Market is expected to reach USD 3,731.03 Million by ... a CAGR of 11.65% between 2015 and 2020. ...
(Date:8/28/2015)... ... 2015 , ... Since the initial launch of FireflySci Inc. (FFS) in early 2015, the company ... Images such as the Fonz in a lab coat and Large Marge have been ... spectroscopy field. , FireflySci is proud to be the only cuvette manufacturer is ...
(Date:8/27/2015)... , Aug. 27, 2015 The ... a patient,s eyes—and life—were saved by doctors at Vanderbilt ... working with NNFF, NovaBay Pharmaceuticals and Dr. John ... Center at Seton Medical Center in ... treatment used a breakthrough approach, pioneered by Dr. Crew, ...
(Date:8/27/2015)... ... August 27, 2015 , ... Inc. Magazine released its annual list of the ... 1,361 in growth for the three years through 2014. Being named to the Inc. ... organizations in the country. , “We are thrilled to make the Inc. 5000 ...
Breaking Biology Technology:Biopreservation Market Worth 3,731.03 Million USD by 2020 2Biopreservation Market Worth 3,731.03 Million USD by 2020 3Biopreservation Market Worth 3,731.03 Million USD by 2020 4Biopreservation Market Worth 3,731.03 Million USD by 2020 5Cuvette Manufacturer FireflySci Launches Back to School Deals with Complimentary Shipping On All Orders 2Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 2Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 3iLab Solutions Named to 2015 Inc. 5000 List 2iLab Solutions Named to 2015 Inc. 5000 List 3
... PALO ALTO and SANTA ROSA, Calif., Feb. 4 ... Medlogics Device Corporation,announced today that the companies have ... CV Therapeutics, proprietary biopolymer stent,coating technology to develop ... stock and is entitled to development milestone payments,royalties ...
... Feb. 4 /Xinhua-PRNewswire-FirstCall/ --,(OTC Bulletin Board: KWBT) Kiwa ... Wei Li, met to discuss cooperative ventures with,members ... Inc. of,Ottawa (Toronto Venture Exchange Symbol: SXS)., ... Li was Dr. Jianqiang,Zhou who is the Chief ...
... (NYSE: WYE ),announced today that it will ... and Medical Device Conference on Thursday,February 7, 2008 ... will be,Geno Germano, President, U.S. Pharmaceuticals & Women,s ... webcast live for investors at, http://www.wyeth.com and ...
Cached Biology Technology:CV Therapeutics and Medlogics Device Corporation Sign Licensing Agreement for CVT's Innovative Stent Coating Technology 2CV Therapeutics and Medlogics Device Corporation Sign Licensing Agreement for CVT's Innovative Stent Coating Technology 3Kiwa Bio-Tech Products Group Discusses Cooperative Efforts With Canadian Agricultural Ministry and Canadian Company 2Kiwa Bio-Tech Products Group Discusses Cooperative Efforts With Canadian Agricultural Ministry and Canadian Company 3Wyeth to Present at the Merrill Lynch 2008 Global Pharmaceutical, Biotechnology and Medical Device Conference 2
(Date:8/5/2015)... The biosensors market is proving highly attractive ... newer sectors, and development of devices resulting in higher ... seen the entry of multiple participants each year with ... (Photo - http://photos.prnewswire.com/prnh/20150805/255570 ) Recent ... Global Biosensors Market ( http://www.frost.com/nee9 ), finds that ...
(Date:8/4/2015)... AMRI ) today reported financial and operating results for the second ... Second quarter contract revenue of $ 85.2 million, ... margins of 26 % , Second quarter ... from royalties in the current quarter , Operating ... pleased to present another strong financial quarter, with all our divisions ...
(Date:7/31/2015)... SHENZHEN , Kina, 31. juli 2015 ... ) bliver afholdt af BGI fra den 22. - 25. ... Konferencen fejrer sin 10-års fødselsdag i år. ... verdens mest indflydelsesrige årlige møder på ,omik,-feltet, og er ... forsamlinger. ICG-10 fokuserer på nylige gennembrud ...
Breaking Biology News(10 mins):Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2
... 23, 2007, President Bush stated that, in order to substantially ... alternative fuels, by setting a mandatory fuels standard to require ... This mandate coupled with a $1.01 ethanol refiner ... subsidy per ton of biomass production for growers are putting ...
... beliefs about inconclusive DNA testing for hereditary breast cancer ... an especially strong predictor of whether women had been ... a study in the October issue of Genetics ... of Medical Genetics (ACMG). The journal is published ...
... rely on friends to help get what they need and, ... the University of Wisconsin-Madison, many microbes, plants and animals benefit ... was funded by the National Science Foundation (NSF) and published ... Science , describes the complex relationship between a beetle, two ...
Cached Biology News:Mandate for biofuels production requires science-based policy and global perspective 2Study looks at psychological impact of gene test for breast cancer 2Study looks at psychological impact of gene test for breast cancer 3Beetles get by with a little help from their friends 2
... Array (MSTA) slides were designed to study protein ... multiple species. Tissue slices from three different ... can then be treated as a single histological ... situ hybridization. This format allows a ...
... MacMelt software is used on ... melting profile of any DNA sequence ... in optimizing placement of primers and ... denaturing gradient gel electrophoresis (DGGE), constant ...
... To score SNPs, Polymorphic uses proven, validated ... in DNA analysis. We use high throughput ... be confirmed by sequencing in both directions. ... sequence context information, further confirming the location ...
... Model 192 and PowerPac basic power supply are ... acids in agarose gels. This Model 192 cell ... cm UV-transparent gel tray with fluorescent ruler, and ... 100-120 and 220-240 V, provides output of 10-300 ...
Biology Products: